UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis

Rheumatology and therapy., 2024-06, Vol.11 (3), p.869-880

2024

Volltextzugriff (PDF)

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Journal of lipid research, 2018-09, Vol.59 (9), p.1640-1648

2018

Volltextzugriff (PDF)

Performance of the SAEM and FOCEI Algorithms in the Open‐Source, Nonlinear Mixed Effect Modeling Tool nlmixr

CPT: pharmacometrics and systems pharmacology, 2019-12, Vol.8 (12), p.923-930

2019

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Emapalumab, a Fully Human, Anti-Interferon Gamma Monoclonal Antibody, in Children with Primary Hemophagocytic Lymphohistiocytosis

Blood, 2020-11, Vol.136 (Supplement 1), p.20-20

2020

Volltextzugriff (PDF)

Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy

Clinical pharmacokinetics, 2017-11, Vol.56 (11), p.1403-1413

2017

Volltextzugriff (PDF)

Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations

Advances in therapy, 2021-10, Vol.38 (10), p.5317-5332

2021

Volltextzugriff (PDF)

Efficacy and safety of emapalumab in macrophage activation syndrome

Annals of the rheumatic diseases, 2023-06, Vol.82 (6), p.857-865

2023

Volltextzugriff (PDF)

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Blood, 2021-11, Vol.138 (Supplement 1), p.2061-2061

2021

Volltextzugriff (PDF)

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers

Clinical pharmacology and therapeutics, 1998-08, Vol.64 (2), p.192-203

1998

Volltextzugriff (PDF)

Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach

British journal of clinical pharmacology, 2022-05, Vol.88 (5), p.2128-2139

2022

Volltextzugriff (PDF)

Evaluation of uncertainty parameters estimated by different population PK software and methods

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.289-311

2007

Volltextzugriff (PDF)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

Journal of viral hepatitis, 2021-12, Vol.28 (12), p.1690-1698

2021

Volltextzugriff (PDF)

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Pharmaceutical research, 2006-09, Vol.23 (9), p.2036-2049

2006

Volltextzugriff (PDF)

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM

British journal of clinical pharmacology, 2024-09, Vol.90 (9), p.2256-2270

2024

Volltextzugriff (PDF)

Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Journal of clinical pharmacology, 2024-10

2024

Volltextzugriff (PDF)

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

Journal of clinical pharmacology, 2015-08, Vol.55 (8), p.866-874

2015

Volltextzugriff (PDF)

A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes

Journal of clinical pharmacology, 2014-03, Vol.54 (3), p.267-278

2014

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Clinical pharmacokinetics, 2007-01, Vol.46 (3), p.221-234

2007

Volltextzugriff (PDF)

Minutes from the round table held at Paris on July 6, 2007

Fundamental & clinical pharmacology, 2008-12, Vol.22 (6), p.609-612

2008

Volltextzugriff (PDF)

Minutes from the round table held in Paris on July 6, 2007: 'Contribution of modelling in the paediatric drug development'

Fundamental & clinical pharmacology, 2008-12, Vol.22 (6), p.609-612

2008

Volltextzugriff (PDF)

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004: Are population PK/PD models adequately evaluated?

Clinical pharmacokinetics, 2007, Vol.46 (3), p.221-34

2007

Volltextzugriff (PDF)

Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis

Journal of pharmacokinetics and pharmacodynamics, 2007-04, Vol.34 (2), p.157-181

2007

Volltextzugriff (PDF)

Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial

Journal of pharmacokinetics and pharmacodynamics, 2005-12, Vol.32 (5-6), p.737-756

2005

Volltextzugriff (PDF)

Use of Nonlinear Mixed Effect Modeling for the Meta‐Analysis of Preclinical Pharmacokinetic Data: Application to S 20342 in the Rat

Journal of pharmaceutical sciences, 2000-05, Vol.89 (5), p.603-613

2000

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis

Efficacy of two vitamin E formulations in patients with abetalipoproteinemia and chylomicron retention disease

Performance of the SAEM and FOCEI Algorithms in the Open‐Source, Nonlinear Mixed Effect Modeling Tool nlmixr

Population Pharmacokinetic Analysis of Emapalumab, a Fully Human, Anti-Interferon Gamma Monoclonal Antibody, in Children with Primary Hemophagocytic Lymphohistiocytosis

Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy

Therapeutic Drug Monitoring Strategies for Envarsus in De Novo Kidney Transplant Patients Using Population Modelling and Simulations

Efficacy and safety of emapalumab in macrophage activation syndrome

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Pharmacokinetic-pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers

Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach

Evaluation of uncertainty parameters estimated by different population PK software and methods

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study

Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide

Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM

Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM

Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

Are population pharmacokinetic and/ or pharmacodynamic models adequately evaluated? : A survey of the literature from 2002 to 2004

Minutes from the round table held at Paris on July 6, 2007

Minutes from the round table held in Paris on July 6, 2007: 'Contribution of modelling in the paediatric drug development'

Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004: Are population PK/PD models adequately evaluated?

Mixture modeling for the detection of subpopulations in a pharmacokinetic/pharmacodynamic analysis

Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial

Use of Nonlinear Mixed Effect Modeling for the Meta‐Analysis of Preclinical Pharmacokinetic Data: Application to S 20342 in the Rat

Suchergebnisse filtern